NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis

RecruitingN/A

Sponsor: Zhejiang Provincial People's Hospital

Conditions: Telitacicept, Treatment Compliance, Rheumatoid Arthritis

Countries: China

The aim of this study is to observe the clinical efficacy and safety of telitacicept combined with baricitinib in the treatment of D2TRA patients

Eligibility overview

Sex: ALL

Age: 18 Years to 85 Years

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* 1\. Age 18-85 years
* 2\. Diagnosed with refractory rheumatoid arthritis according to the 2021 EULAR (European Alliance of Associations for Rheumatology) diagnostic criteria
* 3\. The traditional disease-improving rheumatic drug treatment is ineffective, and the use of two or more biological/targeted disease improving anti-rheumatic drugs is ineffective, and telitacicept combined with tofacitinib is required treated patients
* 4\. Voluntarily provided written informed consent

Exclusion Criteria:

* 1\. Exclusion of patients with severe diseases of major organs (e.g., heart, liver, or lungs)
* 2\. Patients with malignancies, hematological disorders, or other autoimmune diseases (excluding rheumatoid arthritis)
* 3\. History of allergy/hypersensitivity to the study medications (Telitacicept or Tofacitinib)
* 4\. Active tuberculosis or active infectious diseases requiring systemic treatment
* 5\. Pregnancy, lactation, or refusal to use contraception during the study
* 6\. Failure to complete the prescribed Telitacicept + Tofacitinib regimen due
* to:Non-adherence or Severe adverse reactions
* 7\. Other conditions contraindicating participation per investigator judgment

Locations (1)

Hangzhou, Zhejiang, China